March 25, 2019 - NIH Division of AIDS (DAIDS), ABL Inc, Ufovax Inc and Dr. Zhu (on behalf of Scripps Research) held a kickoff meeting to start the cGMP process development for the HIV-1 nanoparticle vaccines developed in Dr. Zhu's laboratory.
February 14, 2019 - Ufovax Inc signed a five-year agreement with Scripps Research to support vaccine development in Dr. Zhu's laboratory.
November 26, 2018 LA JOLLA, CA – A new candidate HIV vaccine from Scripps Research surmounts technical hurdles that stymied previous vaccine efforts, and stimulates a powerful anti-HIV antibody response in animal tests. The new vaccine strategy, described in a paper on November 23 in [...]
Findings Represent ‘Big Accomplishment’ in Biomedical Engineering and Design LA JOLLA, CA – June 28, 2016 – Want to catch a criminal? Show a mugshot on the news. Want to stop HIV infections? Get the immune system to recognize and attack the virus’s tell-tale structure. [...]
LA, JOLLA, CA – April 5, 2016 – Scientists at The Scripps Research Institute (TSRI) and collaborating institutions have described the first-ever immature or “teenage” antibody found in a powerful class of immune molecules effective against HIV. “This is actually the first example of how [...]
NEW YORK (GenomeWeb) – Investigators at the Scripps Research Institute, the International AIDS Vaccine Initiative, and the Ragon Institute of Massachusetts General Hospital have come up with a set of next-generation sequencing techniques for profiling antibody repertoires of immune B cells — collections that provide [...]